Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 26, 2025

Purified anti-mouse/human CD44

RRID:AB_312953
Type: Antibody

Proper Citation

(BioLegend Cat# 103002, RRID:AB_312953)

Antibody Information

URL: http://antibodyregistry.org/AB_312953

Proper Citation: (BioLegend Cat# 103002, RRID:AB_312953)

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, IHC-F, CyTOF®, ELISA, ICC, IHC-P, IP, CMCD, Stim

Antibody Name: Purified anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_312953

Vendor: BioLegend

Catalog Number: 103002

Alternative Catalog Numbers: 103001

Record Creation Time: 20231110T045027+0000

Record Last Update: 20241115T123433+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-mouse/human CD44.

No alerts have been found for Purified anti-mouse/human CD44.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Gray GK, et al. (2023) Single-cell and spatial analyses reveal a tradeoff between murine mammary proliferation and lineage programs associated with endocrine cues. Cell reports, 42(10), 113293.

Jovanovi? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Canella A, et al. (2023) Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment. Cell reports, 42(8), 112891.

Yu S, et al. (2023) Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. Cell, 186(21), 4615.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer cell, 40(5), 509.

Lee JH, et al. (2022) Characterization of adipose depot-specific stromal cell populations by single-cell mass cytometry. iScience, 25(4), 104166.

Snell LM, et al. (2018) CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity. Immunity, 49(4), 678.

Hinohara K, et al. (2018) KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer cell, 34(6), 939.

Lu Y, et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer cell, 33(6), 1048.

An Y, et al. (2018) Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related

Invasive Lobular Carcinoma of the Breast. Cell reports, 25(3), 702.

Gubin MM, et al. (2018) High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy. Cell, 175(4), 1014.

Evrard M, et al. (2018) Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Immunity, 48(2), 364.